ACTUAL NUR 511 EXAM 1 | 2025-2026 LATEST UPDATED | ACTUAL EXAM
QUESTIONS WITH SOLUTIONS | 100% RATED CORRECT | 100% VERFIED
SOLTIONS | ALREADY GRADED A+
1. Breast cancer screening: USPSTF Mammogram Recs
Average risk: Every 2 years beginning at age 50 until age 74
Shared decision making between age 40-49
Mammograms are only beneficial once the breast tissue is less dense and you can actually see
the tissue
2. Cervical cancer screening recs age 21-29: USPSTF Pap Test recs
Age 21-29: pap test alone every 3 yrs -->
,they are against screening for HPV under age 30 because it is going to be positive and cause
worry
3. Cervical cancer screening recs age 30-65: Age 30-65: acceptable to have a pap alone
every 3 yrs
pap and HPV (co-testing) every 5 yrs (preferred)
HPV high risk testing alone every 5 yrs
4. Cervical cancer screening recs age 65+: Age >65 screening is optional when: you
have no hx of mod/sev abn cervical cells/cancer
3 negative pap tests in a row
2 negative co-test results in a row for 10 yrs
5. Cervical cancer screening recs after total hysterectomy (cervix removal):
Recommends against screening for cervical cancer in women who have had a hysterectomy
with removal of the cervix
,AND do not have a history of a high-grade precancerous lesion or cervical cancer
(ie, cervical intraepithelial neoplasia [CIN] grade 2 or 3)
if there was severe cell changes or cancer --> then recommend continued screening for 20 years
6. Cervical cancer screening after DES exposure or HIV: More frequent testing will
be needed. Discuss with provider
Certain risk factors further increase risk for cervical cancer, including HIV infection, a
compromised immune system, in utero exposure to diethylstilbestrol, and previous treatment of
a high-grade precancerous lesion or cervical cancer. Women with these risk factors should receive
individualized follow-up.
7. What is DES?: Diethylstilbestrol is a synthetic non-steroidal estrogen that was
historically widely used to prevent potential miscarriages by stimulating the synthesis of
estrogen and progesterone in the placenta (in the United States of America, especially from the
1940s to the 1970s)
Now banned because there was a strong association between in utero exposure to
, DES and the incidence of rare vaginal and cervical cancer in young women and girls 8. When do
we screen for PSA (prostate specific antigen) in men: Patient make an individual decisio
about whether to be screened after having a conversation with their physician regarding benefits
and harms--age 55-69
PSA can be elevated in BPH or infection
NO SCREENING AFTER AGE 70
Screening offers a small potential benefit of reducing the chance of death from prostate cancer
in some men.
Many men will experience potential harms of screening, including false-positive results (low
specificity) that require additional testing and possible prostate biopsy; overdiagnosis and
overtreatment; and treatment complications, such as incontinence and erectile dysfunction.
In determining whether this service is appropriate in individual cases, patients and clinicians
should consider the balance of benefits and harms on the basis of family history,
race/ethnicity, comorbid medical conditions, patient values about the benefits and harms of
screening and treatment-specific outcomes, and other health needs. Clinicians should not
screen men who do not express a preference for screening.
QUESTIONS WITH SOLUTIONS | 100% RATED CORRECT | 100% VERFIED
SOLTIONS | ALREADY GRADED A+
1. Breast cancer screening: USPSTF Mammogram Recs
Average risk: Every 2 years beginning at age 50 until age 74
Shared decision making between age 40-49
Mammograms are only beneficial once the breast tissue is less dense and you can actually see
the tissue
2. Cervical cancer screening recs age 21-29: USPSTF Pap Test recs
Age 21-29: pap test alone every 3 yrs -->
,they are against screening for HPV under age 30 because it is going to be positive and cause
worry
3. Cervical cancer screening recs age 30-65: Age 30-65: acceptable to have a pap alone
every 3 yrs
pap and HPV (co-testing) every 5 yrs (preferred)
HPV high risk testing alone every 5 yrs
4. Cervical cancer screening recs age 65+: Age >65 screening is optional when: you
have no hx of mod/sev abn cervical cells/cancer
3 negative pap tests in a row
2 negative co-test results in a row for 10 yrs
5. Cervical cancer screening recs after total hysterectomy (cervix removal):
Recommends against screening for cervical cancer in women who have had a hysterectomy
with removal of the cervix
,AND do not have a history of a high-grade precancerous lesion or cervical cancer
(ie, cervical intraepithelial neoplasia [CIN] grade 2 or 3)
if there was severe cell changes or cancer --> then recommend continued screening for 20 years
6. Cervical cancer screening after DES exposure or HIV: More frequent testing will
be needed. Discuss with provider
Certain risk factors further increase risk for cervical cancer, including HIV infection, a
compromised immune system, in utero exposure to diethylstilbestrol, and previous treatment of
a high-grade precancerous lesion or cervical cancer. Women with these risk factors should receive
individualized follow-up.
7. What is DES?: Diethylstilbestrol is a synthetic non-steroidal estrogen that was
historically widely used to prevent potential miscarriages by stimulating the synthesis of
estrogen and progesterone in the placenta (in the United States of America, especially from the
1940s to the 1970s)
Now banned because there was a strong association between in utero exposure to
, DES and the incidence of rare vaginal and cervical cancer in young women and girls 8. When do
we screen for PSA (prostate specific antigen) in men: Patient make an individual decisio
about whether to be screened after having a conversation with their physician regarding benefits
and harms--age 55-69
PSA can be elevated in BPH or infection
NO SCREENING AFTER AGE 70
Screening offers a small potential benefit of reducing the chance of death from prostate cancer
in some men.
Many men will experience potential harms of screening, including false-positive results (low
specificity) that require additional testing and possible prostate biopsy; overdiagnosis and
overtreatment; and treatment complications, such as incontinence and erectile dysfunction.
In determining whether this service is appropriate in individual cases, patients and clinicians
should consider the balance of benefits and harms on the basis of family history,
race/ethnicity, comorbid medical conditions, patient values about the benefits and harms of
screening and treatment-specific outcomes, and other health needs. Clinicians should not
screen men who do not express a preference for screening.
